Related references
Note: Only part of the references are listed.Hepatic Arterial Infusion of Oxaliplatin Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
Qi-Jiong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
Shuling Chen et al.
RADIOLOGY (2021)
A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma
Yuki Bekki et al.
SURGERY (2021)
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
Xiaoyan Ding et al.
CANCER (2021)
Integrated I-125 Seed Implantation Combined with Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus
Wansheng Wang et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2021)
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Peter R. Galle et al.
LANCET ONCOLOGY (2021)
Re-evaluating Transarterial Chemoembolization Failure/Refractoriness: A Survey by Chinese College of Interventionalists
Bin-Yan Zhong et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2021)
Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)
Shuqun Cheng et al.
LIVER CANCER (2020)
Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience
Po-Ting Lin et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma
Feng Duan et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function
Chan Park et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Jae Seung Lee et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo et al.
GUT (2020)
Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis
Chen Shuanggang et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2020)
Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?
Jihye Kim et al.
PLOS ONE (2019)
Safety and Feasibility of Helical I-125 Seed Implants Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas with Main Portal Vein Tumor Thrombus
Wansheng Wang et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2019)
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2019)
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
Victor C. Kok et al.
CANCERS (2019)
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo et al.
CANCERS (2019)
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
Jean-Luc Raoul et al.
CANCER TREATMENT REVIEWS (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Ultraselective conventional transarterial chemoembolization: When and how?
Shiro Miyayama
CLINICAL AND MOLECULAR HEPATOLOGY (2019)
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach et al.
HEPATOLOGY (2018)
Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
Martha M. Kirstein et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
Jin Hyoung Kim et al.
LIVER INTERNATIONAL (2018)
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Masatoshi Kudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma
Roman Kloeckner et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2017)
Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience
Jian Lu et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2017)
Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
Jianbing Wu et al.
ONCOTARGETS AND THERAPY (2017)
Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
Jack P. Silva et al.
HPB (2017)
Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation
Elisabeth G. Klompenhouwer et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2017)
Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5 cm: A propensity score matching study
Minpeng Li et al.
DIGESTIVE AND LIVER DISEASE (2016)
Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process
Xavier Adhoute et al.
JOURNAL OF HEPATOLOGY (2015)
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Joong-Won Park et al.
LIVER INTERNATIONAL (2015)
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Atsushi Hiraoka et al.
ONCOLOGY (2015)
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
Tadaaki Arizumi et al.
LIVER CANCER (2015)
Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization
Takuma Arai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Masatoshi Kudo et al.
ONCOLOGY (2014)
Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
Sadahisa Ogasawara et al.
ONCOLOGY (2014)
How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
Jean-Luc Raoul et al.
LIVER CANCER (2014)
Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis
Tong-Chun Xue et al.
BMC GASTROENTEROLOGY (2013)
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
Takahide Nakazawa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
Wolfgang Sieghart et al.
HEPATOLOGY (2013)
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)
Joong-Won Park et al.
LIVER INTERNATIONAL (2013)
Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses
Gwang Hyeon Choi et al.
RADIOLOGY (2013)
Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
Hana Park et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
Ann-Lii Cheng et al.
EUROPEAN JOURNAL OF CANCER (2012)
Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma
Hwi Young Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?
Christos Georgiades et al.
RADIOLOGY (2012)
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
J. -L. Raoul et al.
CANCER TREATMENT REVIEWS (2011)
Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version
Masatoshi Kudo et al.
DIGESTIVE DISEASES (2011)
Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: Observation on CT during arterial portography
Shiro Miyayama et al.
HEPATOLOGY RESEARCH (2011)
Mixed Phenotype Hepatocellular Carcinoma After Transarterial Chemoembolization and Liver Transplantation
Chikako Zen et al.
LIVER TRANSPLANTATION (2011)
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)
Masatoshi Kudo et al.
HEPATOLOGY RESEARCH (2010)
Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia
Masamichi Kojiro et al.
HEPATOLOGY (2009)
Multistep human hepatocarcinogenesis: correlation of imaging with pathology
Masatoshi Kudo
JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: Comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma
Mikio Tezuka et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features
T Okusaka et al.
CANCER (2002)
Prognostic histologic indicators of curatively resected hepatocellular carcinomas - A multi-institutional analysis of 425 patients with definition of a histologic prognostic index
GY Lauwers et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)